Latest Posts

In vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA 2001 in Patients with Transthyretin Amyloidosis

June 26, 2021 11:37 am Published by Marissa Picerno

CRISPR/Cas9-Mediated Targeted Gene Insertion of SERPINA1 to Treat Alpha-1 Antitrypsin Deficiency

May 11, 2021 6:15 pm Published by Marissa Picerno

Development of In Vivo, Systemic CRISPR-Based Therapeutics

May 11, 2021 6:15 pm Published by Marissa Picerno

Avoiding Unintended Genome Editing for CRISPR/Cas9 Therapeutics

May 10, 2021 4:05 pm Published by Marissa Picerno

Special Edition: Expanding Intellia’s Toolbox with Base Editing

March 25, 2021 12:30 pm Published by Marissa Picerno

Recording: In Vivo Genome Editing of Hematopoietic Stem and Progenitor Cells

March 11, 2021 5:30 pm Published by Tiziani Whitmyre

In Vivo Genome Editing of Hematopoietic Stem and Progenitor Cells

March 10, 2021 11:54 am Published by Marissa Picerno

NTLA-2002: CRISPR/Cas9-Mediated Gene Knockout of KLKB1 for Hereditary Angioedema

February 27, 2021 6:16 pm Published by Marissa Picerno

CRISPR/Cas9 Mediated Targeted Gene Insertion of SERPINA1 to Treat Alpha 1 Antitrypsin Deficiency (AATD)

December 12, 2020 9:00 am Published by Tiziani Whitmyre

NTLA 5001, a T Cell Product Candidate with CRISPR Based Targeted Insertion of a High Avidity, Natural, WT1 Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

December 5, 2020 10:00 am Published by Tiziani Whitmyre

Menu